PHGE News and Press, Chardan Healthcare Acquisition Corp. From 09/06/23

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today anno...

2023-08-09 09:59:08 ET BiomX Inc. (PHGE) Q2 2023 Earnings Conference Call August 09, 2023 08:00 AM ET Company Participants Marina Wolfson - Chief Financial Officer Jonathan Solomon - Chief Executive Officer Conference Call Participants Joe Pantginis - H.C...

2023-08-09 07:43:29 ET BiomX press release ( NYSE: PHGE ): Q2 GAAP EPS of -$0.12 beats by $0.02 . Cash balance, short-term deposits and restricted cash as of June 30, 2023, were $30.7 million, compared to $34.3 million as of December 31, 2022. For further de...

Patient Screening Completed in Part 2 of Phase 1b/2a Trial of BX004 with patient enrollment expected to exceed original estimates FDA grants BX004 Fast Track designation Initial Data from Part 2 Now Expected in November 2023 ...

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Aug. 02, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today annou...

2023-06-09 08:29:41 ET BiomX ( NYSE: PHGE ) has announced that the Co.’s warrants, which have been listed on NYSE American under the ticker symbol, PHGE.WS, are in the process of being delisted. Trading in the Co.’s Warrants was suspended as of Monday, June 5...

CAMBRIDGE, Mass. and NESS ZIONA, Israel, June 08, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today annou...

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announ...

2023-05-15 11:24:07 ET BiomX Inc. (PHGE) Q1 2023 Results Conference Call May 15, 2023 08:00 AM ET Company Participants Marina Wolfson - CFO Jonathan Solomon - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Michael Higgins - Ladenburg...

2023-05-15 06:52:10 ET BiomX press release ( NYSE: PHGE ): Q1 GAAP EPS of -$0.20. Cash balance, short-term deposits and restricted cash as of March 31, 2023, were $30.3 million, compared to $34.3 million as of December 31, 2022. For further details see: Biom...